Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

157
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
157
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

29
Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
29
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

93
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
93
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

119
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
119
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

189
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
189

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Separate Gut Plasma Cell Populations Produce Auto-Antibodies against Transglutaminase 2 and Transglutaminase 3 in Dermatitis Herpetiformis.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2024
Same author

Juvenile myasthenia gravis in Norway: HLA-DRB1*04:04 is positively associated with prepubertal onset.

PloS one·2017
Same author

HLA haplotypes in primary sclerosing cholangitis patients of admixed and non-European ancestry.

HLA·2017
Same author

Migraine and frequent tension-type headache are not associated with multiple sclerosis in a Norwegian case-control study.

Multiple sclerosis journal - experimental, translational and clinical·2017
Same author

HLA class II alleles in Norwegian patients with coexisting type 1 diabetes and celiac disease.

HLA·2017
Same author

Per Brandtzaeg: patron of mucosal immunology.

Mucosal immunology·2017

Related Experiment Video

Updated: Apr 28, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K

Coeliac disease-associated polymorphisms influence thymic gene expression.

S S Amundsen1, M K Viken2, L M Sollid1

  • 1Centre for Immune Regulation, Institute of Immunology, University of Oslo, Oslo University Hospital, Rikshospitalet, Oslo, Norway.

Genes and Immunity
|May 30, 2014
PubMed
Summary
This summary is machine-generated.

Coeliac disease (CD) genetic risk factors may influence T-cell development in the thymus. Our study found CD-associated single nucleotide polymorphisms (SNPs) with regulatory potential in thymic tissue, suggesting a novel role in CD pathogenesis.

More Related Videos

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

Related Experiment Videos

Last Updated: Apr 28, 2026

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
09:08

Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies

Published on: June 2, 2021

1.5K
Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
07:47

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

2.2K

Area of Science:

  • Immunogenetics
  • Molecular Biology
  • Human Genetics

Background:

  • Coeliac disease (CD) is associated with numerous genetic risk regions, primarily containing non-coding single nucleotide polymorphisms (SNPs).
  • Previous expression quantitative trait loci (eQTL) analysis identified cis-regulatory potential for some CD-associated SNPs in peripheral blood mononuclear cells (PBMC).
  • Many CD-associated regions harbor genes involved in immunological pathways, including T-cell development, which has not been extensively studied in CD pathogenesis.

Purpose of the Study:

  • To investigate the regulatory potential of 50 CD-associated SNPs in thymic tissue using eQTL analysis.
  • To explore the role of T-cell development pathways in CD pathogenesis.
  • To identify novel thymus-specific regulatory mechanisms influenced by CD risk polymorphisms.

Main Methods:

  • eQTL analysis was performed on thymic tissue samples from 42 subjects.
  • Fifty CD-associated SNPs were analyzed for their association with gene expression in the thymus.
  • Results were compared with existing eQTL data from PBMC and other tissues.

Main Results:

  • 43 nominally significant eQTLs were identified within 24 CD-associated chromosomal regions.
  • These eQTLs involved 27 expression-altering SNPs (eSNPs) and 39 unique genes (eGenes).
  • Nine significant probe-SNP pairs overlapped with previous PBMC findings, while 14 eQTLs suggested potential thymus-specific regulation.

Conclusions:

  • CD-associated SNPs demonstrate cis-regulatory potential within thymic tissue.
  • These findings implicate T-cell development in the thymus as a potentially relevant pathway in CD pathogenesis.
  • CD risk polymorphisms may exert their effects through gene regulation in the thymus, highlighting a novel aspect of CD genetics.